Andrew Nixon, Boehringer Ingelheim's global head of biotherapeutics discovery
November 29, 2023 02:29 PM EST
Deals
AI

Boehringer In­gel­heim and IBM team up to make an­ti­bod­ies with gen­er­a­tive AI

Ryan Cross

Senior Science Correspondent

Boehringer In­gel­heim is the lat­est drug­mak­er turn­ing to gen­er­a­tive AI for help in mak­ing med­i­cines. On Tues­day, the Ger­man phar­ma gi­ant

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Day af­ter GSK buy­out, IDRx chair takes new in­vest­ing role at Curie.Bio

#JPM25 live blog day 2: Pfiz­er's po­lit­i­cal po­si­tion­ing; The newest bio­phar­mas to watch

Bio­haven’s pro­tein de­grad­er is promis­ing in ear­ly IgAN tri­al, heads straight to Phase 3

Dai­ichi Sankyo brings Gly­co­tope an­ti­body in-house for $132.5M

#JPM25 live blog day 1: How will Trump 2.0 im­pact the bio­phar­ma in­dus­try? Scott Got­tlieb, Bob Nelsen share ...

Up­dat­ed: J&J to buy In­tra-Cel­lu­lar for $14.6B in lat­est neu­ro­science bet

A service from the Financial Times